- Allows NIH to direct up to 15% of its SBIR budget to majority venture owned businesses and allows every other agency to direct up to 5% of its SBIR budget to majority venture owned businesses instead of allowing majority venture owned businesses unfettered access to all SBIR funding.
- Increases Phase I and Phase II award sizes from $100,000 to $150,000 and Phase II award sizes from $750,000 to $1,000,000 instead of $100,000 to $250,000 and $750,000 to $2,000,000 as proposed by H.R. 2965.
Most importantly:
- SBIR must be retained in Phase I for early-stage seed funding, to support pre-prototype feasibility studies--Phase I should be sacrosanct; This issue is not directly addressed in Markey's amendment. H.R. 2965 allows for dangerous precedents in weakening the status of Phase I.
- Increases to allocations should reflect inflation and the higher cost of doing business today, but not raised so high as to severely reduce the number of awards under the program.
- The SBIR allocation as a percentage of agencies' budgets should reflect the value of SBIR for the greater economy, principally it's ability to create and sustain high-quality employment. In this light, a significant increase (at least a doubling or tripling of the current 2.5%) could be easily justified.
No comments:
Post a Comment
Thank you for your interest in Research Entrepreneur. I trust that your comments will be germane to the topic under discussion.
I welcome differences of opinion, but I do require that your comments contribute to open and honest discussion. If not, I retain the right to delete your contribution.
Note: Only a member of this blog may post a comment.